We’d like to go back to the crazy rallies from February, but we have to face the harsh reality of the current major correction, with the main indices as well as the OTCQX Composite, which tracks over 400 OTC stocks, recording their worst month since the start of the pandemic.
Besides the concerns over high inflation and the increasing number of COVID cases, now everyone is talking about the US debt ceiling, as US Secretary of the Treasury Janet Yellen warned that the treasury would run out of cash around October 18 if the federal debt limit was not suspended or increased. Luckily, the debt ceiling was raised, but only until December when we do the same song and dance all over again.
Yellen is supporting the removal of the debt ceiling, but a default could have a negative impact on many people.
Ross Mayfield, investment strategy analyst at Baird, told Reuters:
“The market’s been resilient, but the risk tied up in the policy headlines over the debt ceiling, the chaos around these spending bills is weighing on the markets a bit as the quarter comes to a head. In a larger context it’s been pretty mild. We’re coming on the heels of seven ‘up’ months and volatility’s been fairly muted despite the headline risks, not to mention COVID-19 and tapering. The market had to take a pause, and a pause is necessary and probably to be expected.”
All in all, we should get used to the fact that there will never be consistent ideal market conditions, but that doesn’t mean there are no opportunities. In fact, there are good OTC stock picks at any time, and we do our best to identify those small-cap companies with the most potential for our subscribers.
OTC STOCKS THE PLACE TO BE
Smart investors know that if you want to make the big money off a small account, the place to be is the OTC Markets. There are many good OTC stocks that can boost your portfolio’s value in the long term. For investors, we preach the key to trading penny stocks is finding momentum BEFORE it happens and ahead of the crowd.
We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
We also recommend you own a portfolio of penny stocks. For some, that can be as many as 10 to 20 or more OTC stocks. This provides diversification and allows one to manage the market’s moods much easier. It also helps to own shares in the following 4 hot OTC stocks.
In this article, we look at 4 OTC stocks that will greatly reward patient investors. They are Amani Gold Limited (OTCPK: BRYYF) (ASX: ANL), Enzolytics Inc (OTCPK: ENZC), Icoa, Inc (OTCPK: ICOA), and JZZ Technologies, Inc (OTCPK: JZZI).
OTC STOCK TO WATCH #1 BRYYF
Amani Gold Limited has had a great run starting with the last of September, with the Pink Current stock gaining 121% during the last five trading days. The share price has surged from $0.0012 on September 29 to the current level of $0.0031, peaking on Friday at half of a penny, which is the highest level since mid-February.
We drew your attention to BRYYF at the beginning of September, when the OTC stock, which is also listed on the Australian Stock Exchange (ASX), was trading at less than $0.002.
The company is targeting exploration at its flagship project, the Giro Gold Project, located within the significant yet under-explored Moto greenstone belt in the Democratic Republic of Congo (DRC).
BRYYF started to get more attention as investors found out that the small company sits on $8 billion of gold reserves.
In the previous post, we explained that it was quite difficult to assess the actual value of the company since the figures from ASX and OTC Markets differ. Also, the company used to issue securities from time to time, creating conditions for dilution.
Nevertheless, CEO Klaus Peter Eckhof said a few months ago that Amani would be back on track after “cleaning up the Chinese mismanagement.” It will start to post on OTC Markets soon.
Anyway, the concerns regarding Amani’s reporting and share structure are negligible if it can reap the full benefits of its gold reserves.
On September 30, the company released its annual report, confirming that the Giro Gold Project global resource for Kebigada and Douze Match deposits exceeds 4.4 million ounces contained gold, which means about $8 billion.
We have high expectations of BRYYF, although not in the immediate future. So this is a great OTC stock to hold with long-term target in mind, especially when Meryll Lynch owns about 14% of the company’s shares, along with other major institutions that are locking up shares, leaving fewer shares floating.
$BRYYF : This is the other key aspect that really stuck out to me…
▪️12billion OS increased to a 14billion OS for Funding.
▪️2 Billion is held by @MerrillLynch.
▪️9.4 Billion Held all together by similar institutions.
▪️Leaves about 4.8 Billion Actually Floating/Trading. https://t.co/XM7RoAzYwN pic.twitter.com/BaRE6TvxZw
— ☀️Alex Sunderland☀️ (@SUNNYLAND24) September 30, 2021
OTC STOCK TO WATCH #2 ENZC
Readers who check our recommendations on a regular basis already know that discussing Enzolytics Inc from time to time has turned into a routine for us. Indeed, we’re quite bullish on ENZC despite the fact that larger timeframes point to a long-term correction since February. However, this is the right time to get exposure to this OTC stock sitting on a pile of patents and IP, as buying the dip is what we constantly preach.
ENZC is already showing its teeth after finding support at the beginning of September. The share price has gained over 30% since then, currently trading at $0.17.
We got our subscribers in on ENZC last year in October at just $.014 a share, helping many of our subscribers secure generous profits before the correction from the YTD high. Those who didn’t exit then, rest sure that another rally is just around the corner, as ENZC is developing multiple therapies and has pending patents.
Last year, ENZC merged with BioClonetics, which marked the start of a great collaboration of two experienced teams developing treatments against infectious diseases.
ENZC patented anti-HIV therapeutics and applies its proprietary methodology to produce human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. ENZC has tested its anti-HIV therapeutics and has developed a proprietary cell line that generates human monoclonal antibodies that neutralize HIV. We explained in an extensive analysis why ENZC’s HIV therapeutics are better than Gilead’s products that have monopolized the space.
Following the merger with BioClonetics, ENZC adopted its proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, influenza A, influenza B, rabies, tetanus, diphtheria, and even the coronavirus causing COVID-19.
Meanwhile, ENZC has made some progress in developing monoclonal antibodies that can target all types of the HTLV-1 virus, which causes a rare form of cancer.
Take a look at ENZC’s drug development pipeline to understand the great potential this company has:
At the end of September, ENZC COO Dr. Gaurav Chandra shared some details about the partnership with Riin Ehrin as the company expands its presence in personalized and precision medicine markets. Ehrin has led personalized medicine initiatives in Estonia, working with the country’s Ministry of Health.
He also said that the company was successfully using artificial intelligence (AI) to detect immutable parts of viruses that could be targeted by its monoclonal antibodies. Chandra specified that the company determined 19 immutable sites of COVID-19 after analyzing over 2 million isolates of all variants, including Delta. ENZC claims that its monoclonal antibodies are universal and cannot allow the virus escape. The company is already testing its COVID treatment in pre-clinical trials, with more updates to come next year.
Besides COVID, the company used AI to identify immutable sites on 20 viruses. Chandra went on to say that ENZC was capable of preventing the next pandemic thanks to its AI platform and the monoclonal antibodies.
He also confirmed that the company was preparing for uplisting. You can watch the full interview here:
We continue to be bullish on ENZC and consider current levels a discount entry opportunity. On top of that, it has a great share structure that prevents dilution.
OTC STOCK TO WATCH #3 ICOA
Icoa, Inc has been making waves recently as the company is working to redefine itself. The share price has surged by 400% during the last month alone and has gained about 20,000% since the beginning of the year. ICOA rose from $0.015 on Wednesday to $0.020 on Friday, after peaking at $0.026 during the same day, which is the highest level in over a decade.
Earlier this week, ICOA updated its status from Pink Limited Information to Pink Current.
Previously, ICOA used to be a national provider of wireless and wired broadband Internet network support for broadband access installations in high-traffic locations across the US including, quick-service restaurants, hotels, and motels, travel plazas, marinas, etc.
At the end of August, the company announced that it would undergo a reorganization in order to facilitate a new direction and the implementation of a new business plan to create new value for shareholders, although the existing business seems to carry on. More details will be shared with investors as developments take place, but what we know so far is that the new direction will focus on blockchain, Decentralized Finance (DeFi), and crypto space – which together make the fastest-growing and most exciting industry as of today.
On October 1, ICOA announced that it had executed a Letter of Intent (LOI) to acquire iBG Finance, which is promoted as the world’s first and currently only insured DeFi project, in a transaction valued at $185 million. This is huge news for a company worth slightly less than that.
$ICOA Signs LOI for 185 Million Acquisition of IBG Finance#Defi #MergersAndAcquistionshttps://t.co/uPnj9O5WIv
— Icoa Inc (@icoa_inc) October 1, 2021
Launched in September last year, iBG is a DeFi wealth management platform designed to bring simplicity to users interested in entering the cryptocurrency and the DeFi market. iBG is equipped with the latest Robo Advisory technology to offer algorithm-driven recommendations.
The iBG App is a smart yield aggregator platform, providing an intuitive user experience to make it easy for all users to benefit from their digital tokens/cryptocurrencies. The App is offered as a customized recommendation engine by simplifying user experience to provide non-tech savvy users a way to interact with various crypto and DeFi assets that are built on blockchains. In traditional finance and portfolio management, users can obtain advice and use automated platforms to enrich their trading strategies.
As part of the acquisition, ICOA will be acquiring 100% of iBG Finance in return for restricted preferred shares of ICOA.
This is great news that makes us bullish on ICOA, especially as it cancels billions of shares.
2.59 Billion Share Cancellation Happening This Week. Official PR to follow. pic.twitter.com/WjxzrWxuVS
— Icoa Inc (@icoa_inc) September 29, 2021
OTC STOCK TO WATCH #4 JZZI
JZZ Technologies, Inc has had some difficult months after peaking in mid-February at over 4 cents, but the company seems to recover after hitting the highest level since May a few days ago. On September 16, JZZI broke above two pennies for the first time in 4 months, and then it almost touched the two-cent mark again last Thursday before correcting to the current level of $0.011.
Like ICOA, JZZI has updated its OTC status from Pink Limited Information to Pink Current earlier this week.
The $5 million business is a diversified technology company rolling up projects and partnerships in two distinct business sectors that operate cohesively:
- Its digital media business includes online media and apps (activelifestylemedia.com), content creation, digital marketing, streaming video content, publishing, and free over-the-air television (EyeOnTV) targeted at active adults 55+.
- JZZI’s other business focuses on strategic biotechnology and bioscience acquisitions related to Human Life Extension and Human Longevity that can be immediately leveraged to support improved quality of life for aging populations.
Last week, we reported that the stock price surged to its swing high after the company’s marketing division had received an independent assessment of its proprietary marketing database, indicating that the total record group has a base asset value of $13+ million, which is quite a lot for a $5 million company.
In August, JZZI said that it was expanding into Human Life Extension and Human Longevity sectors by targeting biotech and bioscience companies for M&As and partnerships. The company confirmed that it had no intention of diluting its current share structure and that it was working on updating the necessary filings. In light of this, JZZI, in partnership with EverConvert, launched its redesigned website targeting audiences age 55+ at activelifestylemedia.com. The new site is built around increased audience engagement and generating direct revenue through digital marketing and e-commerce opportunities.
On Thursday, the price peaked on the news that JZZI had acquired Florida insurance agency Beacon Insurance Solutions, Inc., including its human resources, IP, access to contracts, licenses, and all product offerings. Beacon is an established St. Petersburg, Florida insurance agency positioned in a geographic hotspot that people strive their entire lives to retire in. It is also an ideal hub for the target demographics of JZZ Technologies’ 55+ age group audiences.
Beacon Insurance currently has five full-time agents providing a range of services geared to seniors. Founder and head of Beacon Insurance Solutions, Tom Law, has 25 years of experience developing successful insurance and financial services companies. He said:
“Following this acquisition by JZZ Technologies, Inc. I expect we will be able to increase the number of producing agents by adding between five to ten new agents by the end of the year and continuing our growth strategy through 2022. Conservatively speaking, by blending the capabilities of the two business operations – Beacon with insurance products and support services and JZZ Technologies with digital marketing channels – I see achieving a high six-figure monthly revenue stream as a very obtainable expectation within the first six months.”
JZZI is gathering attention on social media, which is very important. Recently, an investor with over 100k followers on Twitter praised both JZZI and BRYYF.
Alright guys… I have $CEI
I also have TWO #OTC ideas 💡 $BRYYF Looks like the float I’d locked up by insiders. Should go back to .003+$JZZI news this morning if insurance company acquisition. Super low floater good for a few Pennies swing pic.twitter.com/NrFUpiXsKP
— LADE BACKK (@LadeBackk) September 30, 2021
THE FINAL NOTE
All of the 4 OTC stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever a penny stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye the best OTC stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.